JPRN-UMIN000024267已完成3 期
Phase III trial of a single early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III) - Phase III trial of a single early intravesical instillation of pirarubicin in the prevention of bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III)
Japan Clinical Oncology Group (JCOG)0 个研究点目标入组 310 人开始时间: 2016年10月3日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 310
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •First registration (no exclusion criteria at second registration) 1. Synchronous or metachronous (within 5 years) malignancies. 2. Infectious disease requiring systemic treatment. 3. Pyrexia of 38 degrees centigrade or higher. 4. Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy. 5. Severe psychological disorder. 6. Receiving continuous systemic corticosteroid or immunosuppressant treatment. 7. History of abnormal cardiac function or having received the limit dose of medications with cardiac toxicity such as anthracyclines. 8. Positive HIV antibody.
研究者
相似试验
招募中
1 期
Investigation of the safety and efficacy of the optimized measles virus vaccine in bladder tumor healingIRCT20230903059342N1Kian Gen Azma Company10
已完成
3 期
Injectable Male ContraceptiveCTRI/2019/08/020680Indian Council of Medical Research303
已完成
不适用
Phase I/IIa study of intravesical administration of 2-methyl-3-butenyl-1-pyrophosphate-stimulated gamma delta T cells in patients with non-invasive bladder cancer.on-invasive bladder cancerJPRN-UMIN000010942Tokyo Women's Medical University12
进行中（未招募）
1 期
Assessing the safety of atezolizumab being directly administered to the bladder in bladder cancer patients undergoing radical cystectomyrothelial cell carcinoma of the bladderCancerISRCTN15842444Sheffield Teaching Hospitals NHS Foundation Trust56
已完成
不适用
A randomised phase III study of intravenous (i.v.) zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsMultiple myelomaCancerISRCTN23172547Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)407